Novartis (NVS) Set to Announce Earnings on Thursday

Novartis (NYSE:NVS) is scheduled to post its quarterly earnings results before the market opens on Thursday, April 19th. Analysts expect Novartis to post earnings of $1.33 per share for the quarter.

Novartis (NYSE:NVS) last released its quarterly earnings results on Wednesday, January 24th. The company reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.04. The company had revenue of $12.92 billion for the quarter, compared to analyst estimates of $12.65 billion. Novartis had a net margin of 15.69% and a return on equity of 16.03%. The firm’s revenue was up 4.8% on a year-over-year basis. During the same period last year, the firm earned $1.14 earnings per share. On average, analysts expect Novartis to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

How to Become a New Pot Stock Millionaire

Shares of NVS stock opened at $81.17 on Tuesday. The stock has a market capitalization of $187,806.64, a price-to-earnings ratio of 16.88, a P/E/G ratio of 1.82 and a beta of 0.74. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.91 and a current ratio of 1.21. Novartis has a 52 week low of $72.67 and a 52 week high of $94.19.

Several brokerages have commented on NVS. JPMorgan Chase reaffirmed a “neutral” rating on shares of Novartis in a research report on Monday, April 9th. Deutsche Bank reaffirmed a “neutral” rating on shares of Novartis in a research report on Tuesday, April 10th. UBS reaffirmed a “neutral” rating on shares of Novartis in a research report on Monday, January 15th. Zacks Investment Research lowered shares of Novartis from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Finally, Nord/LB reaffirmed a “neutral” rating on shares of Novartis in a research report on Wednesday, December 27th. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $87.51.

TRADEMARK VIOLATION WARNING: This report was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Earnings History for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with's FREE daily email newsletter.

Leave a Reply